- Recommendation ID
- Can vitamin D slow down the progression of disability in Multiple Sclerosis (MS)?
- Any explanatory notes
- Despite considerable success with agents that substantially reduce relapse frequency in the initial inflammatory, relapsing–remitting phase, over half of people eventually develop non-relapsing, secondary progressive MS 1 to 2 decades after the onset of relapsing–remitting MS. While a variety of symptomatic treatments is available, progression in secondary progressive MS is currently intractable, and immunomodulatory strategies used for relapsing–remitting MS have not proven effective when extended into secondary progressive MS (for example, beta interferon). Direct neuroprotection strategies (for example tetrahydrocannabinol) have also been ineffective. The critical and as yet unmet challenge therefore is to find effective and well-tolerated treatments for secondary progressive MS.
Source guidance details
- Comes from guidance
- Multiple sclerosis in adults: management
- Date issued
- October 2014
|Is this a recommendation for the use of a technology only in the context of research?||No|
|Is it a recommendation that suggests collection of data or the establishment of a register?||No|